<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1264">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621149</url>
  </required_header>
  <id_info>
    <org_study_id>Profact-01</org_study_id>
    <nct_id>NCT04621149</nct_id>
  </id_info>
  <brief_title>An Outpatient Study Investigating Non-prescription Treatments for COVID-19</brief_title>
  <acronym>PROFACT-01</acronym>
  <official_title>A Phase 2 Screening Study of Candidate Non-prescription Treatments for COVID-19: A Patient-driven, Randomized, Factorial Study Evaluating Patient-reported Outcomes (PROFACT-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profact, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Profact, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a platform study to investigate the effectiveness of a variety of non-prescription&#xD;
      approaches for the treatment of non-hospitalized adults recently tested positive for&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will screen for the activity of a variety of non-prescription approaches for the&#xD;
      treatment of non-hospitalized adults recently diagnosed with COVID-19. This will be a&#xD;
      randomized, blinded placebo-controlled study with respect to the active treatment (chlorine&#xD;
      dioxide) vs placebo, and randomized open-label with respect to a non-prescription medication&#xD;
      (famotidine) and supplements including zinc, EGCG and lactoferrin. Treatment will last for 7&#xD;
      days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, blinded placebo-controlled study with respect to the active treatment vs placebo, and randomized open-label with respect to non-prescription medicine and supplements.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Participant Symptoms of COVID-19</measure>
    <time_frame>3 days</time_frame>
    <description>Symptoms of COVID-19 will be evaluated daily using a visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Participants will complete a daily assessment for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalization</measure>
    <time_frame>28 days</time_frame>
    <description>Admission to Hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen Saturation</measure>
    <time_frame>8 days</time_frame>
    <description>Oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Temperature</measure>
    <time_frame>8 days</time_frame>
    <description>Body temperature</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 liter of filtered water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chlorine dioxide aqueous solution (AS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with AS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo with zinc acetate (ZA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with ZA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS with ZA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with AS and ZA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo with famotidine, lactoferrin and green tea extract (FLG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with FLG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS with FLG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with AS and FLG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo with ZA and FLG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with ZA and FLG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS with ZA and FLG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 liter of filtered water with AS, ZA, and FLG</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chlorine dioxide</intervention_name>
    <description>chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.</description>
    <arm_group_label>AS with FLG</arm_group_label>
    <arm_group_label>AS with ZA</arm_group_label>
    <arm_group_label>AS with ZA and FLG</arm_group_label>
    <arm_group_label>chlorine dioxide aqueous solution (AS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zinc acetate</intervention_name>
    <description>zinc acetate lozenges have been suggested to have antiviral properties</description>
    <arm_group_label>AS with ZA</arm_group_label>
    <arm_group_label>AS with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with zinc acetate (ZA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid</description>
    <arm_group_label>AS with FLG</arm_group_label>
    <arm_group_label>AS with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with famotidine, lactoferrin and green tea extract (FLG)</arm_group_label>
    <other_name>Pepcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>filtered water</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>placebo with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with famotidine, lactoferrin and green tea extract (FLG)</arm_group_label>
    <arm_group_label>placebo with zinc acetate (ZA)</arm_group_label>
    <other_name>filtered water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lactoferrin, green tea extract</intervention_name>
    <description>lactoferrin and green tea extract are dietary supplements</description>
    <arm_group_label>AS with FLG</arm_group_label>
    <arm_group_label>AS with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with ZA and FLG</arm_group_label>
    <arm_group_label>placebo with famotidine, lactoferrin and green tea extract (FLG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 20-70&#xD;
&#xD;
          4. Confirmed diagnosis of COVID-19 by positive COVID-19 test. Symptoms of a mild degree&#xD;
             such that hospitalization is not required. Within 7 days of symptom onset.&#xD;
&#xD;
          5. Ability to drink at least 1 liter of water daily and be willing to adhere to the study&#xD;
             regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. COVID-19 symptoms of a severe enough nature that requires hospitalization&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Diagnosis of diabetes mellitus&#xD;
&#xD;
          4. currently taking paroxetine or digoxin&#xD;
&#xD;
          5. Individuals with diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Murphy, MD, MD(H)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profact, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Murphy, MD, MD(H)</last_name>
    <phone>3047670150</phone>
    <email>jonathan@pro-fact.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mitchell B Liester, MD</last_name>
    <phone>7193385719</phone>
    <email>mitchell.liester@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Good Health Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Murphy, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>December 27, 2020</last_update_submitted>
  <last_update_submitted_qc>December 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
    <mesh_term>Chlorine dioxide</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

